APOE and Alzheimer disease: Furthermore, the APOE ε4/ε4 carriers accounted for 11.8% of Alzheimer’s continuum and 14.2% of biomarker-confirmed AD, which were higher than those previously reported in studies based on only clinical AD criteria (Ward et al., 2012; Yamazaki et al., 2019).